The ASCO Post Podcast

Latest Episodes:

ESMO Congress 2021: News in Genitourinary Cancers Sep 27, 2021

Show notes

This week, we explore more findings presented during the virtual ESMO Congress 2021—specifically, data in genitourinary oncology. We’ll hear from researchers on the efficacy and safety of abiraterone acetate added to different regimens for different types of prostate cancer, as well as patient-reported quality of life with adjuvant pembrolizumab vs placebo for renal cell carcinoma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

High-Impact Research From the ESMO Congress 2021 Sep 20, 2021

Show notes

On September 16th, the virtual ESMO Congress 2021 began. This week, we’ll hear from the authors of three influential, late-breaking studies presented at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

News From the IASLC 2021 World Conference on Lung Cancer Sep 13, 2021

Show notes

This week, we’re hearing about three abstracts presented during the IASLC 2021 World Conference on Lung Cancer, focusing on clinical trial enrollment during the COVID-19 pandemic, air pollution's role in lung cancer risk, and strategies for reducing barriers and improving cancer care in low-resource areas.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Withdrawal of Atezolizumab's Indication for Metastatic Triple-Negative Breast Cancer Sep 03, 2021

Show notes

This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.

Coverage of stories discussed this week on ascopost.com:

Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Recent FDA Approvals: dMMR Solid Tumors and von Hippel Lindau–Associated Cancers Aug 27, 2021

Show notes

This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Breakthrough COVID-19 Infection in Vaccinated Health-Care Workers Aug 23, 2021

Show notes

This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy.

Coverage of stories discussed this week on ascopost.com:

Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers

Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Presentations From the 2021 Pan Pacific Lymphoma Conference Aug 09, 2021

Show notes

On this episode, we’re hearing from experts presenting data on hematologic malignancies during the 2021 Pan Pacific Lymphoma Conference, which begins on August 9 and concludes on August 13.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Defining Cure in Multiple Myeloma Jul 30, 2021

Show notes

Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further.

Coverage of stories discussed this week on ascopost.com:

Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Recommendations on the Use of Liquid Biopsy for Lung Cancer Jul 23, 2021

Show notes

On this episode, we’re reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We’ll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer.

Coverage of stories discussed this week on ascopost.com:

Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC

SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approval in Urothelial Cancer, Plus Mechanisms of Acquired Resistance in KRAS G12C–Mutant Cancers Jul 16, 2021

Show notes

This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.